Professionals 206 Users Online

Ineffective Esophageal Motility Treatment Market

Growth in Hiatal Hernia are Driving the Ineffective Esophageal Motility Treatment Market

Ineffective Esophageal Motility Treatment Market by Product (Devices and Drugs)

Ineffective Esophageal Motility Treatment Market Outlook (2023 to 2033)

The global revenue from the Ineffective Esophageal Motility Treatment Market was around US$ 3.95 Billion in 2022, with the global market expected to grow at a CAGR of 5.9% to reach a valuation of about US$ 7.47 Billion by the end of 2033.

Market Size (2023)

US$ 4.21 Billion

Projected Market Value (2033)

US$ 7.47 Billion

Global Market Growth Rate (2023 to 2033)

5.9% CAGR

Market Share of Top 5 Countries

65.0%

As assessed by Persistence Market Research, drugs segment held around 97.6% in the global market, in 2022. The global ineffective esophageal motility treatment market holds nearly 23.1% revenue share of the global ENT treatment market valued at US$ 17.12 Billion in 2022.

Sample Report

FREE Report Sample is Available

In-depth report coverage is now just a few seconds away

Download PDF Get FREE Report Sample

Sales Analysis of Market from 2015 to 2022 Vs Market Outlook for 2023 to 2033

The global market recorded a historic CAGR of 5.4% in the last 7 years from 2015 to 2022.

The global market is likely to show high growth over the coming years at a CAGR of 5.9% and reach a global market size of 7.47 Billion by 2033.

Increasing prevalence of GERD, also known as gastroesophageal reflux disease has been one of the main factors responsible for the growth of ineffective esophageal motility treatment market over the years.

Regurgitation and heartburn are two common symptoms of gastroesophageal reflux disease (GERD). A common medical disorder called asthma often co-occurs with gastroesophageal reflux disease. Asthma and gastroesophageal reflux have complicated relationships and interactions that may make asthma symptoms more common, and cause or exacerbate GERD. Persons with asthma frequently have higher rates of GERD symptoms when compared to the general population.

The effectiveness of various gastroesophageal reflux treatment methods and devices has been investigated in several research and clinical trials. Clinical studies have aided patients in getting a clear view of the situation and making better treatment decisions for gastroesophageal reflux disease, and this creates a growth opportunity for the market.

Rising treatment demand for gastrointestinal problems, dysphagia, GERD, burning chest discomfort, and achalasia, as well as an ageing population has caused the global market for ineffective esophageal motility treatment to expand.

Both emerging markets and developed economies would experience faster growth throughout the projected period in the market for ineffective esophageal motility treatments.

Key manufactures are also involved in the activities to tackle such disorders.

  • For instance, in the longest-term study on magnetic sphincter augmentation (MSA) ever published, Ethicon, a subsidiary of Johnson & Johnson Medical Devices Companies, reported in 2020 that its LINX Reflux Management System had been shown to continue providing efficient control of gastroesophageal reflux disease (GERD) for the long term and to eliminate 79% of daily medication for the reflux in patients.
Custom Report Cover

Make This Report Your Own

Take Advantage of Intelligence Tailored to your Business Objective

> Get a Customized Version

How Can the Global Market Grow?

Increasing Prevalence of GERD, Hiatal Hernia and Abdominal Obesity”

Obesity, or excess belly fat, has been identified as being one of the leading causes of gastroesophageal reflux disease in several studies.

Obesity is a complicated disease with high mortality and morbidity. Obesity is frequently associated with gastroesophageal reflux disease (GERD), which strikes 20% of adults in the United States of America.

  • According to the study " A Systematic Review of Non-Pharmacological Interventions Role and Gastroesophageal Reflux Disease, Weight Loss Management in Obese Individuals, Cureus 2022," 15% to 25% of people worldwide suffer from GERD. In Western countries, including the United States, the prevalence of GERD ranges from 10% to 30%, which is higher than in Asia.

Another key factor propelling the market for ineffective esophageal motility treatments is the growing elderly population. Due to issues with esophageal motility and decreased saliva production, esophageal acid clearance may be reduced in the elderly. Age-related declines in salivary production lead to a markedly reduced response of salivary bicarbonate to esophageal acid perfusion.

Dysphagia and trouble swallowing are among the typical symptoms experienced by the ageing population. They are connected to a number of illnesses that affect the elderly more frequently, such as oropharyngeal dysphagia, Parkinson's disease, cerebrovascular disease, and diabetes.

The emergence of acid reflux and the transformation of acid reflux into the chronic condition known as gastroesophageal reflux are both significantly influenced by hiatal hernia. Lower esophageal sphincter weakness brought on by a hiatal hernia might result in stomach contents backing up into the esophagus. A hiatal hernia occurs when a small gap in the diaphragm allows a part of the stomach to push through. Hiatal hernia may result from the existence of weakened supporting tissues.

Many patients are underserved in emerging economies, including South Africa, Brazil, China, Mexico, Brazil, and India. Medical device businesses have a great opportunity in these regions. Patient disposable income and economic gain in these emerging nations will contribute to the market's long-term viability. Similarly, increased medical infrastructure and medical investment by various governments would enable the installation and usage of advanced medical equipment in healthcare institutions such as hospitals.

Market Research Methodology

Market Research Methodology

-Perfect through Years of Diligence

Check Research Methodology

Can the Market Growth Be Affected in Any Way?

“Adverse Effects of Surgical Treatment and High Treatment Cost”

Anti-reflux fundoplication procedures generally have obstructive mechanical side effects. A number of patients experience difficulty swallowing. Another adverse effect associated with anti-reflux fundoplication is the difficulty in passing air from the stomach, which makes it difficult to burp, thus causing more gas to pass through the intestine. This results in bloating.

The market for ineffective esophageal motility treatment is predicted to rise slowly because of the high price of gastroscopes and esophagoscopes as well as the threat of infection. One of the sections of medical equipment that is frequently linked to the development of healthcare infections is contaminated endoscopes. Before storing, esophagoscopes and gastroscopes must be thoroughly cleaned and dried.

Since most endoscopes used in gastroenterology have numerous channels and are not heat sterilized, they are challenging to clean. They are also exceedingly difficult to clean and have limited lumens. Blood, bodily fluids, and other microorganisms are expected to be heavily present on these devices.

The clinical success rate of surgical devices for gastroesophageal reflux disease treatment is very low. This factor might hamper the global market growth over the forecast duration.

Sales Team

Sales Team
Client Partner

Let's Connect

Connect me to identify winning opportunities

Ask An Expert
I'm Available

Country-wise Insights

Why is the United States Market Booming?

“Rising Obese Population Leading to the GERD Induced Injuries in the Country.”

The United States accounted for around 43.1% market share in the global market in 2022.

Obesity may increase the risk of esophageal cancer and inflammation through mechanisms unrelated to reflux, and it may make the esophageal mucosa particularly vulnerable to damage from GERD.

  • According to Central for Disease Control and Prevention (CDC) projections, the prevalence of obesity in the United States rose from 30.5% to 41.9% between 2017 and March 2020. Throughout that time span, the incidence of severe obesity rose from 4.7% to 9.2%.

The market is driven by esophageal injuries, which could result from an increased prevalence of obesity.

Will China Be a Lucrative Market for Ineffective Esophageal Motility Treatment?

“Growing Prevalence of Dysphagia”

The China market held around 7.0% share of the global market in 2022.

  • As per “Prevalence of Dysphagia in China: An Epidemiological Survey of 5943 Participants. Dysphagia. 2021”, dysphagia prevalence continuously rises with advancing age and the presence of concomitant illnesses in China.

Dysphagia is becoming more common in China, especially among the elderly and those who have had strokes. As people age and have more illnesses, the prevalence of dysphagia continuously rises.

How is Germany Emerging as a Prominent Market?

“Rising Cases of Esophageal Disorders.”

Germany held a market share of about 5.7% of the global market in 2022.

The increasing consumption of beverages like alcohol and coffee is leading to an increase in esophageal disorders in the country. Such beverages develop acid reflux symptoms, or a heartburn, a chronic symptom for GERD. This will fuel the market for esophageal motility treatment in Germany.

  • According to Calendar Canada 2023, the average annual coffee consumption in Germany is 160 liters.
  • The Movendi International office reported in 2019 that the average alcohol consumption in Germany is equivalent to 700 bottles of beer

Category-wise Insights

Which Product is Driving Demand within the Global Market?

“Effectiveness, Safety, and Accessibility as Over-the-counter Medications.”

The drugs segment held around 97.6% share of the total market in 2022.

One or more of the classic signs of gastroesophageal reflux include acid regurgitation and heartburn. Due to their effectiveness, safety, and accessibility as over-the-counter drugs, drugs like anticholinergics, nitrates, calcium channel blockers, beta-blockers, and phosphodiesterase inhibitors are still frequently used to treat the symptoms of gastric reflux despite the wide range of therapeutic options available. The symptoms of heartburn, hyperacidity, acid indigestion, GERD, and an upset stomach are alleviated with antacids.

Which Indication Drives High Demand For Ineffective Esophageal Motility Treatment?

“Changes in Patients' Lifestyles are Hastening the Onset of GERD”

GERD segment held around 45.6% share of the total market in 2022.

A persistent digestive illness called gastroesophageal reflux disease is defined by the vomiting of contents from the stomach into the esophagus. The increase in GERD prevalence is due to consumption of certain types of food and drinks, smoking and lack of physical activities.

  • According to an article called "Prevalence of Gastroesophageal Reflux Disease and Associated Risk Factors in the Eastern Region, Saudi Arabia, submitted in Cureus 2021," the prevalence of gastroesophageal reflux disease in the overall population of Saudi Arabia's Eastern region was 20.6%. Several sociodemographic and lifestyle factors have been linked to the disease.

Why Retail Sales Is Dominating the Global Market?

“Easy Availability of Drugs in Retail Pharmacies”

Retail sales held around 79.7% of the total market share in 2022.

When stomach acid leaks back up into the esophagus or food pipe, it is known as "acid reflux," a problem that affects many people. As a result, the person experiences heartburn, a burning discomfort in the lower chest area.

In retail pharmacies, there are numerous OTC products available to address the signs and symptoms of GERD. H2 blockers, antacids, prokinetics, and proton pump inhibitors are few of them that are attracting customers, thus propelling growth in the retail sales segment.

Competition Landscape

To increase ineffective esophageal motility treatment offerings and strengthen consumer base, the market players are involved in activities like increased clinical trials and product certification as well as product launches. Also, key market players in the industry are focusing on their distribution channels to expand their geographic reach.

  • The Echelon+ Stapler, a new assisted surgical stapler, was introduced in 2021 by Ethicon, a subsidiary of Johnson & Johnson Medical Device Companies. It is intended to improve tissue deformation and staple formation even in difficult situations, thereby enhancing staple line security and minimizing complications.
  • The latest Endocyto colonoscope and gastroscope were introduced by Olympus Medical Systems (Tokyo, Japan) at Arab Health 2020, the biggest healthcare expo in the Middle East.
  • For the supply and commercialization of its Tegoprazan, which is approved for gastrointestinal illnesses in India and some emerging markets, Dr. Reddy's Laboratories has come into an exclusive cooperation with South Korean-based HK inno.N Corporation in May 2022.

Similarly, the team at Persistence Market Research has tracked recent developments related to companies in the ineffective esophageal motility treatment market, which are available in the full report.

Ineffective Esophageal Motility Treatment Industry Report Scope

Attribute

Details

Forecast Period

2023 to 2033

Historical Data Available for

2015 to 2022

Market Analysis

  • USD Million for Value
  • Units for Volume

Key Countries Covered

  • United States
  • Canada
  • Brazil
  • Argentina
  • Mexico
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • BENELUX
  • India
  • Thailand
  • Malaysia
  • Indonesia
  • China
  • Japan
  • South Korea
  • Australia
  • New Zealand
  • Türkiye
  • GCC Countries
  • North Africa
  • South Africa

Key Market Segments Covered

  • Product
  • Indication
  • End User
  • Region

Key Companies Covered

  • Johnson & Johnson
  • Mylan Pharmaceutical
  • MediGus Ltd
  • Dr. Reddy’s Laboratories Ltd.
  • Torax Medical
  • Medtronic Plc
  • AstraZeneca Plc
  • Teva Pharmaceutical Industries Ltd
  • Takeda Pharmaceutical Company Limited
  • Glaxosmithkline Plc.
  • Bayer Ag
  • Pfixer Inc
  • Bausch Health Companies Inc.
  • Laborie
  • Mederi Therapeutics, Inc.
  • Becton, Dickinson and Company.
  • EndoGastic Solution Inc
  • Olympus
  • Pentax

Report Coverage

  • Market Forecast
  • Competition Intelligence
  • DROT Analysis
  • Market Dynamics and Challenges
  • Strategic Growth Initiatives

Customization & Pricing

Available upon Request

Key Segments Covered in Ineffective Esophageal Motility Treatment Industry Research

Product:

  • Devices
    • Reflux Management Systems
    • Endoscopic Pain Modulators
    • Endostaplers
    • Radiofrequency (RF) Ablation Devices
    • Myotomy
  • Drugs
    • H2 Receptor Antagonist
    • Antacids
    • Proton Pump Inhibitors
    • Dopamine Antagonist
    • Prokinetic Agents
    • Calcium Channel Blockers

Indications:

  • Dysphagia
  • GERD
  • Burning chest pain
  • Achalasia

End User:

  • Institutional sales
    • Hospitals
    • Ambulatory Surgical Centers
  • Retail Sales
    • Retail Pharmacies
    • Drug Stores
    • Mail order Pharmacies

Region:

  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • Middle East and Africa

- Companies Covered in This Report -

  • Johnson & Johnson
  • Mylan Pharmaceutical
  • MediGus Ltd
  • Torax Medical
  • Medtronic Plc
  • AstraZeneca Plc
  • Teva Pharmaceutical Industries Ltd
  • Takeda Pharmaceutical Company Limited
  • Glaxosmithkline Plc.
  • Bayer Ag
  • Pfixer Inc
  • Bausch Health Companies Inc.
  • Laborie
  • Mederi Therapeutics, Inc.
  • Becton, Dickinson and Company.
  • EndoGastic Solution Inc
  • Olympus
  • Pentax

- Frequently Asked Questions -

The global market is currently valued at around US$ 3.95 Billion in 2022.

The global market estimates for 2023 is around US$ 4.21 Billion.

The global market is set to reach a valuation of around US$ 7.47 Billion by the end of 2033.

Sales of the market are set to witness growth at a CAGR of 5.9% between 2023 and 2033.

Demand for the global market increased at 5.4% CAGR from 2015–2022.

The U.S., China, Germany, France, and India account for around 65.0% of revenue share globally.

The U.S. accounts for around 43.1% share of the global market in 2022.

The China ineffective esophageal motility treatment market held around 7.0% market share in 2022.

The ineffective esophageal motility treatment market in Germany held around 5.7% market share in 2022.

This site uses cookies, including third-party cookies, that help us to provide and improve our services. Privacy Policy
Google translate